HCPLive

Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF

Oct 12, 2026 · 0:06:00

Listen to Episode

✨ AI Summary

Tovinontrine increased cGMP in HFpEF patients in the Cycle-2-PEF trial.
The drug did not lower NT-proBNP at the highest dose.
Data presented by James Udelson, MD, at HFSA 2026.

Guests on This Episode

JM

James Udelson, MD

2 podcast appearances

More from HCPLive

Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites

Oct 12, 2026 · 0:03:18

Targeting Senescent Cells in Actinic Keratosis With RLS-1496

Oct 12, 2026 · 0:04:25

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

Oct 12, 2026 · 0:03:33

Hemophilia A Care Beyond Zero Bleeds, With Doris Quon, MD, PhD

Oct 12, 2026 · 0:05:52

View all episodes →